Abide Therapeutics Inc.

Autobahn Therapeutics wanted to take advantage of the neuropsychiatric benefits observed with thyroid hormone therapy without systemic side effects, so the company used its proprietary technology for

Bristol Myers Squibb Company is under pressure to bring new drugs to market before several of its current blockbuster products face generic and biosimilar competition. But in addition to a suite of l

Teva Pharmaceutical Industries Ltd. ’s attempts to add a “meaningful” additional market for one of its newer specialty brands, Austedo, have hit the buffers after two late-stage studies failed to show

As it consolidates two major neuroscience acquisitions, Lundbeck Inc. is ready to enter the next phase of growth as it waits for an imminent decision in the US on eptinezumab for the prevention of m